CardioCel calcification-free after six years: Admedus

Admedus (ASX:AHZ) revealed that the first patient implanted with its CardioCel heart patch during a phase II trial has reached six-year follow-up with no detectable calcification issues.

The patient was implanted at three weeks old and has had no complications, such as the requirement for ‘re-do’ surgery.

All other patients from the trial are showing no sign of calcification after between three and five years. The patients from the trial will continue to be monitored annually for signs of calcification and overall health.

Admedus CEO Lee Rodne said the results show that CardioCel has “huge potential for the future treatment of congenital heart disease and other cardiac defects”, noting that the data “demonstrates the longer-term benefits of using CardioCel and its superiority over alternatives”.

CardioCel is a cardiovascular scaffold used to repair paediatric and adult heart deformities. Admedus produces the product using its proprietary ADAPT tissue engineering process. The lack of calcification is the product’s major advantage over other tissue treatment processes on the market.

CardioCel was awarded FDA approval in February and a CE Mark in Europe in August last year. The product is also being used in Australia under the TGA’s Authorised Prescriber Scheme.

Admedus (ASX:AHZ) shares were trading 1.6% lower at $0.127 as of around 3 pm on Thursday